This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Creating adequate capacity for any therapeutic can be challenging, and the specialized technologies for manufacturing complex biologics require flexibility and agility in production processes.
For cell and gene therapy applications, you need a variety of speciality enzymes of the highest purity, specificity, and consistency. Developing best-in-class speciality enzymes. Novozymes has a long legacy of enzyme discovery and the ability to genetically engineer these speciality enzymes to be superior.
Antibody-drug conjugates are a promising biopharma modality but specialized expertise is instrumental for successfully bringing drugs to the clinic. Over the last several decades, mounting interest has positioned bioconjugate therapeutics as one of the most promising biopharmaceutical modalities.
The startup specializes in a type of machine learning called reinforcement learning. BioNTech says its InstaDeep acquisition will help it expand its use of artificial intelligence in drug discovery and development.
Forge specializes in manufacturing AAV vectors used to deliver these therapies. Ajinomoto’s Forge Biologics acquisition brings contract development and manufacturing organization capabilities in gene therapy.
Season 2 of the MedCity Pivot Podcast has launched with a special focus on the evolution of pharmacy and pharmacy benefit management. The first guest this season is A.J. Loiacono, who leads Capital Rx. The post Pivot Podcast: A Conversation with Capital Rx CEO A.J. Loiacono appeared first on MedCity News.
A new report by the Association of the British Pharmaceutical Industry (ABPI) has identified the UK biopharma industry is increasingly seeking talent with artificial intelligence (AI) and data skills to maintain competitiveness as digital technology continues to drive innovation. This has spiked from 27 in 2019 to 225 in 2022.
Thermo Fisher Scientific’s acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers and immune system disorders. It’s Thermo Fisher’s biggest acquisition since its 2021 buyout of contract research organization PPD.
Breakthroughs in therapies containing monoclonal antibodies (mAbs) are showing ever-greater potential in treating a range of diseases, alongside biopharma manufacturers facing the challenge of keeping up with demand for production while controlling costs. This can result in reductions in costs for our customers.” Download to learn more.
Single-use filtration systems can help streamline processes and enhance efficiency of biopharma production. Sterile filtration: The crucial line of defence against life-threatening microorganisms, with insights into diverse membrane technologies and specialized viral clearance solutions. Interested to know more?
Speciality pharmacies play a crucial role in medication dosing, disease and side effects management, and patient care. Speciality pharmacies provide comprehensive medications for individuals with serious medical conditions requiring complex treatments, including cancer, cystic fibrosis, haemophilia, hepatitis, HIV, and others.
The appeal of process intensification continues to grow in the biopharma industry as a means of not only increasing the productivity, but also improving sustainability. Chromatography and clarification play vital parts in biopharma manufacturing, yet there is room for improvement in processes to eliminate inefficiencies and increase yield.
Nevertheless, the potential for mAb therapies in treating medical conditions that have limited options means that biopharma companies are investing considerable resources in development. The post Overcoming challenges with scalability in biopharma manufacturing appeared first on Pharmaceutical Technology. Download to learn more.
For more information about how Baxter BioPharma Solutions manufacturing expertise can support your project, download the content below. The post How a specialized commercial program management team can improve your customer experience and accelerate commercialization appeared first on Pharmaceutical Technology.
How do you see the evolution of cannabis-based medicines, particularly when it comes to the ‘specials’ or fully licensed drug routes? In the short term, the unique advantage the cannabis-based medicines sector has – unlike many other biopharma businesses – is the ability to get to revenue through the ‘specials’ framework.
The unit will specialize in medical communications, medical affairs, real-world evidence, and outcomes research. It includes agency groups ApotheCom, Ashfield MedComms, and Nucleus Group as well as specialized medical services companies MediStrava and MedEvoke.
The public listing market slumped to nine initial public offerings (IPOs) and five special purpose acquisition company (SPAC) deals in 2022, but partnering remained buoyant, with more than 2,900 deals signed. Roche tops biopharma partnering podium.
Big Pharma accounted for about 77 percent of M&A spending in the biopharma sector in the second quarter. The biopharma industry has well over a trillion dollars in Firepower (a metric that measures a company’s deal-making capacity based on the strength of its balance sheet).
ZyVersa Therapeutics has signed a definitive business combination agreement with blank-check special purpose acquisition company (SPAC) Larkspur Health Acquisition. The deal, which will make ZyVersa a publicly traded biopharma company, values the merged entity at an estimated pro forma enterprise value of nearly $108.92m.
Myovant Sciences has rejected an acquisition offer worth $2.5bn from Sumitovant Biopharma and its wholly-owned subsidiary Sumitomo Pharma, citing it 'significantly undervalues' the company. The board of directors of Myovant constituted a special committee of independent directors including its audit committee members to assess the proposal.
Before becoming an investor, Dr. Yu was a senior research scientist at Wyeth BioPharma, where she specialized in therapeutic protein development. Yu worked for Vision Capital, an NYC-based investment management firm, as a Director of Investment, responsible for US biotech and China sectors.
Nearly every biopharma with a portfolio of drugs in development spanning traditional small molecules and biologics and the newer CGT operates with separate clinical supply organizations per these therapy areas. CGT have highly unique and specialized manufacturing processes.
Whether you are a start-up looking for investment or are interested in working in venture capital (VC), the worldwide biopharma and MedTech industries are growing. In 2022, over $14 billion was funded in biopharma setup globally, and 37 major IPOs of VC-backed biotech company businesses raised a combined $4.2 The Venture Capitals.
Sunny’s healthcare marketing agency, Xavier Creative House, specializes in pharmaceutical, biotech, and medical device. Extension of the patient: expanding the role of caregivers in biopharma development. Reach out at swhite@xaviercreative.com. Connect at linkedin.com/in/sunnywhite/ . REFERENCES: Gilda’s Club. Accessed March 12, 2022.
As two in five pharma leaders say that moving to a consumer-first mindset is a priority for the next two years, digital customer experience agency Graphite Digital is to publish a special edition of its Contradiction Conundrum whitepaper report, released in partnership with Reuters Events Pharma last year.
Eligible companies classified as start-ups and active in the pharma, biopharma, digital, or medical device sectors can exhibit. This special edition will introduce three new categories, acknowledging the remarkable wave of innovation that has engulfed the industry.
Managing the complexity of commercializing rare and orphan therapies requires specialized Marketing, Medical Affairs, and Market Access teams that are up to the task. Acknowledgements: Special thanks to Sonalee Agarwal, VP, Alnylam Pharmaceuticals, and Crystal Watson, Head of HEOR, Atara Bio for their contributions to this article.
Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC) that has screened over 100 European biotechnology companies.
The health-conscious among us pay special attention to actively managing our sleep, exercise, vitamins, etc. Biopharma should pay special attention to this. Biopharma companies that bring patients together in-person can create a sense of belonging and support that is often missing in the digital realm. The list goes on.
Therapeutic inhibition of NLRP3 can prevent the formation of the NLRP3 inflammasome, which in turn inhibits the production of pro-inflammatory cytokines like interleukin-1 beta and interleukin-18, and has attracted a lot of attention among biopharma companies.
Those in the biopharma industry can play a pivotal role in shortening the journey to diagnosis if they learn from patients what critical pieces had to fall into place before they were diagnosed. It’s also in these communities where biopharma finds the best opportunities to connect with their stakeholders.
The MedTech/Biopharma industry is a unique place where individuals get to make meaningful contributions that (if safe and efficacious) has real world impacts on real people needing help. MedTechVets Academy is a specialized program that provides more than generic advice about transitioning into medical-related career fields.
A form of artificial intelligence (AI) specialized in voice cloning used Travis’ voice, as recorded over a decades-long career, to fill in the vocals of the song. Yet from a risk-mitigation perspective, we anticipate a cautious, measured approach by most biopharma companies. In the patient engagement space, the potential is immense.
April 6, 2021 The biopharma industry rightfully places a great deal of emphasis on the importance of having a sales compensation plan that pays for performance. In order to truly pay for performance, a biopharma sales compensation plan must be designed such that it meets the following two attributes: Pay-for-Performance Attributes.
With gene therapies, like any specialized treatment, payers are going to be very stringent in making sure patients meet the criteria for treatment, given the cost they’re carrying,” said Kiernan. Payers are also eyeing a variety of stringent utilization management measures to prevent unnecessary care and rein in costs.
In order to improve patient inclusivity in clinical trials, the biopharma industry must incorporate DEI in all processes. Baseline lab tests are common, but diagnostic testing, such as ECG, echocardiogram, and Ocular Coherence Tomography requiring specialized devices, have found their way into product labels and REMS programs.
This, in turn, calls for a more expert and specialized sales force. This calls for a more specialized and expert sales force, requiring longer and more rigorous hiring and training processes. Thus, one role of a rare disease sales force is education on the rare disease and its diagnosis.
We at The Marketing Advantage have been designing call plans based on sales, opportunity, potential, maintenance and growth for the biopharma industry for over 30 years. Part of Dynamic Targeting™ is giving sales representatives the freedom to make or not make that special effort as they see fit.
Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. According to Deloitte , 76% of biopharma companies invest in AI for clinical development. How is AI used in the pharmaceutical industry?
Special software that takes DICOM images from CT scanners and creates a treatment plan, defines the distribution of the Alpha DaRT sources within the tumor. This year it is scheduled for May 16-18, 2023 in Tel Aviv, and topics range from medical robotics, to bio-convergence, to the impact of AI on biopharma.
Although expert opinions differ on the future of special purpose acquisition companies (SPACs), some companies are continuing to explore their use. In December 2022, AEON Biopharma, a biopharmaceutical company, announced its plans to go public through a merger with the SPAC Priveterra Acquisition Corp.
The confluence of highly specialized oncology care and new locations in Wisconsin’s primary and secondary markets has expanded Froedtert’s reach and reputation—which will be critical as local rival Advocate Aurora prepares to merge with North Carolina-based Atrium Health. Stephanie Hoops, Senior Healthcare Research Analyst.
This will be achieved via highly specialized analytics and unique expert insights. A: Clarivate and Dialog have complementary and synergistic product portfolios that, when combined, will enable us to support the drug, device and medical technology landscape from research through to outcome.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content